Evidence map›Paper›PMID 31148199›Full record

Trial reportJournal of cutaneous pathology2019

Loss of ZNF750 in ocular and cutaneous sebaceous carcinoma.

Jeffrey P North, David A Solomon, Justin Golovato, Michele Bloomer, Stephen C Benz, Raymond J Cho

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cutaneous pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jeffrey P NorthDepartment of Dermatology, University of California, San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0003-3973-5314
David A SolomonDepartment of Pathology, University of California, San Francisco, San Francisco, California.
Justin GolovatoNantOmics, LLC, Santa Cruz, California.
Michele BloomerDepartment of Pathology, University of California, San Francisco, San Francisco, California.
Stephen C BenzNantOmics, LLC, Santa Cruz, California.
Raymond J ChoDepartment of Dermatology, University of California, San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0001-6090-6603
University of California, San Francisco · USUniversity of California, Santa Cruz · US

Funding

Cohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0M
NIH HHS DP5 OD021403UCSF Department of DermatologyUCSF Physician-Scientist Scholar Program
6 · The paper itself

Abstract

backgroundSebaceous carcinoma (SeC) is an uncommon malignancy arising from sebaceous glands of the conjunctiva and skin. Recurrent mutations in the ZNF750 were recently identified in ocular SeC. We assessed whether ZNF750 loss is a specific feature of ocular SeC or a general feature of sebaceous tumors.

methodsImmunostaining for ZNF750 expression was performed in 54 benign and malignant sebocytic proliferations. Staining for ZNF750 was scored on a three-tier scale: positive (>75%), partially positive (5%-74%), and negative (<5%).

resultsZNF750 expression was negative in 4/11 ocular SeC, and partially positive in 4/11 ocular SeC and 6/13 cutaneous SeC. No extraocular tumors were negative. No loss was found in sebaceous adenoma or sebaceous hyperplasia. In nine previously sequenced ocular SeCs, two lacked detectable somatic mutations in ZNF750, but showed complete loss of staining, indicating non-mutational inactivation of ZNF750.

conclusionWe show complete loss of the ZNF750 epidermal differentiation regulator in about half of ocular SeC, highlighting the most common genetic defect in this cancer type. Loss of ZNF750 expression is seen even in tumors without truncating mutations and reduced in many of the remaining ocular and cutaneous SeC. In contrast, no ZNF750 loss was detected in benign sebaceous proliferations.

Indexed as

Adenocarcinoma, SebaceousEye NeoplasmsGene Expression Regulation, NeoplasticSebaceous Gland NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm ProteinsTranscription FactorsTumor Suppressor ProteinsNeoplasm ProteinsTranscription FactorsTumor Suppressor ProteinsZNF750 protein, humansebaceous adenomasebaceous carcinomaZNF750

Identifiers

PMID31148199
PMCPMC6744339
OpenAlexW2947462437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.